Neurocrine Biosciences has recently announced that its pipeline asset, Ingrezza (valbenazine), achieved the primary endpoint of reducing the symptoms of chorea (involuntary muscle movements) associated with Huntington’s disease (HD) in the Phase III clinical trial, KINECT-HD (NCT04102579). This will propel Ingrezza into a dominant position in the HD market, due to its convenient once-daily dosing…
Category: Industry News
WFNR celebrates 25th anniversary
“Congratulations to the WFNR for all that it has achieved over the last 25 years. Today the WFNR is a true advocate for neurorehabilitation” said Professor David Good, WFNR President as the organisation celebrates its 25th anniversary. He continued: “We’re extremely grateful to all our members who have contributed to the success of the organisation…
Aphasia: guide to digital communication tools
News from The Stroke Association
ACT Myself -supporting mental health in MS
Biogen launches ACT Myself – a free digital self-help tool to support the mental health of people living with multiple sclerosis (MS) as NHS highlights rise in anxiety among patients Biogen has launched a free, new, digital self-help tool to help people living with multiple sclerosis (MS) navigate the emotional challenges of life with the…
ONGENTYS®▼ (opicapone) demonstrates significant efficacy in the early stages of motor fluctuations in PD patients
News from Bial at the EAN Congress
FDA approves ONGENTYS® ▼ (opicapone)
News from Bial
Neurodiem, a new digital platform of independent, high-quality scientific content for UK neuro practitioners
News from Biogen Inc.
BNA Journal Indexing
News from the British Neuroscience Association
Fampyra® (fampridine) becomes first treatment funded by NHS Scotland to improve walking difficulties in adult patients with all types of multiple sclerosis (MS)
News from Biogen
